HCS 465 Week 5 Influences on Health Care Research Example

Who Decides What Gets Studied? Funding, Industry Sponsorship, Politics and Technology as Influences on Health Care Research, and What They Mean for a Manager Reading the Evidence

[Student Name]

University of Phoenix

HCS/465: Health Care Research Utilization

Week 5 Assignment

[Instructor Name]

[Date]

The management example at the end is a composite written for a model paper; research findings come from the sources listed.

Health care managers are told to use evidence. But the evidence available to them is not a neutral sample of everything worth knowing. Some questions are studied again and again, others hardly at all, and the results of some studies lean in predictable directions depending on who paid for them. This paper examines four influences on health care research, funding, industry sponsorship, politics and public priorities, and technology, and explains what each means for a manager reading the evidence.

Influence 1: Who Pays

Moses et al. (2015) analyzed funding for medical research in the United States and found that total funding reached about $117 billion in 2012, equal to about 4.5% of total health care spending. Growth had slowed sharply after 2004. Private sources, mainly pharmaceutical, biotechnology and device companies, provided 58% of the total, up from 46% in 1994. Industry concentrated on late-stage clinical trials and products, particularly for cancer and rare diseases. Health services research, the study of how care is organized, delivered and paid for, received only about $5 billion, roughly one twentieth of science funding and about 0.3% of health spending.

For managers, this matters directly. The questions they care most about, how to staff a unit, schedule a clinic or reduce readmissions, fall mostly within health services research, the least funded part of the enterprise, so the evidence for many management decisions is thinner than the evidence for a new drug.

Influence 2: Industry Sponsorship

When companies fund research on their own products, results tend to favor those products. Lundh et al. (2017), in a Cochrane methodology review of 75 papers, found that drug and device studies sponsored by the manufacturer more often reported favorable efficacy results, with a risk ratio of 1.27, and more often reached favorable conclusions, with a risk ratio of 1.34, than studies with other sponsors. The authors noted that this bias was not explained by the standard risk-of-bias tools used to appraise trials, which suggests it arises through choices such as comparison drugs, outcomes selected and which results are published.

Industry funding also produces real advances; many effective drugs and devices exist because companies paid for the trials. The lesson is not to ignore sponsored research but to read it with attention to who designed it, what it compared the product against and whether independent studies agree.

Influence 3: Politics and Public Priorities

Public funding follows public and political attention. Moses et al. (2015) observed that National Institutes of Health funding correlated imperfectly with disease burden, with some conditions receiving support out of proportion to their share of illness. Advocacy groups, congressional priorities and public events all shape where federal money goes. During the COVID-19 pandemic, research priorities shifted almost overnight. Politics can also limit research, as when legal restrictions constrain study of controversial topics.

Influence 4: Technology and Data

Technology is changing research quickly. Electronic health records, claims databases and registries allow studies of millions of patients at low cost, and faster computing supports methods that were once impractical. These data make it possible to study everyday care, including management questions, in ways that were not possible a generation ago. They also bring new risks: data collected for billing may be inaccurate for research, and large samples can make trivial differences look significant (Creswell & Creswell, 2018).

Influence 5: Publication and Visibility

Even after a study is done, influences shape whether anyone sees it. Studies with positive, striking results are more likely to be published, and published faster, than studies that find no effect, a pattern known as publication bias. Trial registries and requirements to report results have reduced the problem, but not eliminated it. For a manager, the practical consequence is that a handful of enthusiastic published reports may overstate how well an intervention works, because less encouraging results never appeared. Searching trial registries and asking vendors for all studies, not only the published ones, helps correct for this.

Influences Inside the Organization

Organizations influence their own evidence too. When a department evaluates a program its leader championed, there is pressure to find success. Internal reports may choose flattering measures or time periods. Managers can guard against this by setting measures before a change begins, asking someone outside the program to analyze the data and reporting results whether they are good or bad.

Reading Evidence With These Influences in Mind

A manager can turn these influences into questions. Who funded the study, and did the funder benefit from a particular result? What was the product compared against, and were the outcomes the ones that matter to patients and the organization? Has anyone without a stake replicated the findings? Is the question important but understudied, so that the absence of evidence reflects funding gaps rather than a proven lack of effect? Were the data collected for research or for another purpose?

An Example: A Vendor's Claim

A vendor offers a hospital an electronic sepsis alert and cites a study showing a large drop in sepsis deaths. Applying the questions, the manager learns that the vendor funded the study, that it compared outcomes before and after installation at a single hospital that simultaneously launched a sepsis education program, and that no independent evaluation has been published. The claim may be true, but the evidence cannot separate the product from the education program. The manager asks for a pilot with defined measures before a system-wide purchase. The vendor's study is not discarded; it becomes one piece of evidence to be tested locally, with the hospital's own data as the judge.

Conclusion

Funding decides which questions are asked, sponsorship can tilt answers, politics shifts priorities and technology changes what can be studied. None of these makes research untrustworthy, but each shapes it. A health care manager who understands the influences can use evidence wisely, asking not only what a study found but why it was done and who stood to gain.

References

Creswell, J. W., & Creswell, J. D. (2018). Research design: Qualitative, quantitative, and mixed methods approaches (5th ed.). SAGE Publications.

Lundh, A., Lexchin, J., Mintzes, B., Schroll, J. B., & Bero, L. (2017). Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews, 2017(2), Article MR000033. https://doi.org/10.1002/14651858.MR000033.pub3

Moses, H., III, Matheson, D. H. M., Cairns-Smith, S., George, B. P., Palisch, C., & Dorsey, E. R. (2015). The anatomy of medical research: US and international comparisons. JAMA, 313(2), 174-189. https://doi.org/10.1001/jama.2014.15939